- Home
- SNTI vs DPRO Comparison
SNTI vs DPRO Comparison
Compare SNTI & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- DPRO
- Stock Information
- Founded
- SNTI 2016
- DPRO 1998
- Country
- SNTI United States
- DPRO Canada
- Employees
- SNTI N/A
- DPRO N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- DPRO Aerospace
- Sector
- SNTI Health Care
- DPRO Industrials
- Exchange
- SNTI Nasdaq
- DPRO Nasdaq
- Market Cap
- SNTI 21.3M
- DPRO 17.3M
- IPO Year
- SNTI N/A
- DPRO N/A
- Fundamental
- Price
- SNTI $3.96
- DPRO $2.80
- Analyst Decision
- SNTI Strong Buy
- DPRO Strong Buy
- Analyst Count
- SNTI 1
- DPRO 2
- Target Price
- SNTI $12.00
- DPRO $7.00
- AVG Volume (30 Days)
- SNTI 30.3K
- DPRO 130.9K
- Earning Date
- SNTI 03-20-2025
- DPRO 03-26-2025
- Dividend Yield
- SNTI N/A
- DPRO N/A
- EPS Growth
- SNTI N/A
- DPRO N/A
- EPS
- SNTI N/A
- DPRO N/A
- Revenue
- SNTI N/A
- DPRO $4,340,793.00
- Revenue This Year
- SNTI $11.52
- DPRO $14.33
- Revenue Next Year
- SNTI $78.57
- DPRO $115.93
- P/E Ratio
- SNTI N/A
- DPRO N/A
- Revenue Growth
- SNTI N/A
- DPRO N/A
- 52 Week Low
- SNTI $1.52
- DPRO $1.55
- 52 Week High
- SNTI $16.94
- DPRO $9.13
- Technical
- Relative Strength Index (RSI)
- SNTI 45.36
- DPRO 37.04
- Support Level
- SNTI $3.92
- DPRO $3.09
- Resistance Level
- SNTI $4.50
- DPRO $3.34
- Average True Range (ATR)
- SNTI 0.26
- DPRO 0.26
- MACD
- SNTI -0.03
- DPRO -0.02
- Stochastic Oscillator
- SNTI 20.59
- DPRO 2.80
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.